Andrew Phillips is President and Chief Executive Officer of Aleksia Therapeutics, Inc. and Nexo Therapeutics, Inc. Previously, Dr. Phillips was Managing Director at Cormorant Asset Management, LP and Chief Financial Officer of Helix Acquisition Corp. Before joining Cormorant, he was the President and Chief Executive Officer of C4 Therapeutics (NASDAQ: CCCC). Prior to joining C4 Therapeutics, Dr. Phillips was Senior Director, Center for Development of Therapeutics at The Broad Institute of MIT and Harvard. Previously, he was a Professor of Chemistry at Yale University and a Professor of Chemistry and Biochemistry at the University of Colorado. Dr. Phillips holds Ph.D. and B.Sc. Hons. degrees in Chemistry and Biochemistry from the University of Canterbury (Christchurch, New Zealand).
